MapLight Therapeutics, Inc. (MPLT)Healthcare | Biotechnology | Redwood City, United States | NasdaqGS
12.60 USD
+0.06
(0.478%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 12.60 |
Hot Take ↕ | Aug. 22, 2026, 2:14 a.m. EDT
MapLight Therapeutics presents a catastrophic long-term investment case driven by deteriorating clinical realities and a broken business model. The company recently suffered massive share price declines following mixed Phase 2 schizophrenia data and disappointing trial results, signaling that its core assets may not deliver the necessary therapeutic breakthroughs. Fundamentally, the picture is dire: the stock trades at a negative forward P/E with negative earnings, negative free cash flow, and a return on equity of -111%. The balance sheet, while currently showing low debt, is propped up by cash reserves that are being rapidly consumed by operating losses, leaving no runway for recovery without significant dilution or capital raising. The technical structure confirms this bearish thesis, with the stock trading well below its 50-day and 200-day moving averages, indicating sustained selling pressure. While analysts maintain 'Strong Buy' ratings based on potential future upside, this ignores the immediate reality of a failing drug pipeline and eroding shareholder value. The options market reflects this fear, with traders buying deep puts to hedge against further collapse. There is no dividend to provide income, and the lack of recent price history in the provided data masks the severity of the recent multi-month decline. This is a value trap where the low price reflects a fundamental failure of the business, not a margin of safety. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.593904 |
| AutoARIMA | 0.593929 |
| MSTL | 0.594726 |
| AutoTheta | 0.625720 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 24% |
| H-stat | 38.26 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.029 |
| Excess Kurtosis | -1.90 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.57 |
| Market Cap | 584,360,704 |
| Forward P/E | -3.78 |
| Website | https://www.maplightrx.com |
As of Aug. 22, 2026, 2:14 a.m. EDT: Speculators are aggressively positioning for downside protection with heavy put volume and open interest concentrated at strikes significantly below the current price (e.g., $7.50 and $10.00), while call activity is sparse and focused on deep out-of-the-money strikes. This imbalance suggests a market consensus expecting further price weakness rather than a catalyst-driven rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.31297708 |
| Address1 | 800 Chesapeake Drive |
| All Time High | 40.43 |
| All Time Low | 9.1 |
| Ask | 15.75 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 634,900 |
| Average Daily Volume3 Month | 835,349 |
| Average Volume | 835,349 |
| Average Volume10Days | 634,900 |
| Bid | 9.03 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 7.666 |
| City | Redwood City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 12.6 |
| Current Ratio | 16.523 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 12.835 |
| Day Low | 12.2 |
| Debt To Equity | 0.57 |
| Display Name | MapLight Therapeutics |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -242,343,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.162 |
| Enterprise Value | 281,622,688 |
| Eps Current Year | -4.596 |
| Eps Forward | -3.33539 |
| Eps Trailing Twelve Months | -20.06 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 23.804 |
| Fifty Day Average Change | -11.204 |
| Fifty Day Average Change Percent | -0.4706772 |
| Fifty Two Week Change Percent | -31.297707 |
| Fifty Two Week High | 40.43 |
| Fifty Two Week High Change | -27.83 |
| Fifty Two Week High Change Percent | -0.6883502 |
| Fifty Two Week Low | 9.1 |
| Fifty Two Week Low Change | 3.5 |
| Fifty Two Week Low Change Percent | 0.38461536 |
| Fifty Two Week Range | 9.1 - 40.43 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,761,571,800,000 |
| Float Shares | 17,040,607 |
| Forward Eps | -3.33539 |
| Forward P E | -3.7776692 |
| Free Cashflow | -95,213,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 133 |
| Fullday Change | 0.0600004 |
| Fullday Change Percent | 0.478472 |
| Fullday Price | 12.6 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.63293 |
| Held Percent Institutions | 0.55711 |
| Implied Shares Outstanding | 46,377,832 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,025-10-27 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California. |
| Long Name | MapLight Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 584,360,704 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_605975835 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -229,827,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 581,578,012 |
| Number Of Analyst Opinions | 13 |
| Open | 12.49 |
| Operating Cashflow | -174,668,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 617 984 6300 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 12.6 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 12.54 |
| Price Eps Current Year | -2.7415144 |
| Price Hint | 2 |
| Price To Book | 1.6436212 |
| Profit Margins | 0.0 |
| Quick Ratio | 15.794 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.35714 |
| Region | US |
| Regular Market Change | 0.0600004 |
| Regular Market Change Percent | 0.478472 |
| Regular Market Day High | 12.835 |
| Regular Market Day Low | 12.2 |
| Regular Market Day Range | 12.2 - 12.835 |
| Regular Market Open | 12.49 |
| Regular Market Previous Close | 12.54 |
| Regular Market Price | 12.6 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 375,074 |
| Return On Assets | -0.67112 |
| Return On Equity | -1.1155 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 43,650,321 |
| Shares Percent Shares Out | 0.0698 |
| Shares Short | 3,235,957 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 3,586,196 |
| Short Name | MapLight Therapeutics, Inc. |
| Short Percent Of Float | 0.14050001 |
| Short Ratio | 2.41 |
| Source Interval | 15 |
| State | CA |
| Symbol | MPLT |
| Target High Price | 45.0 |
| Target Low Price | 13.0 |
| Target Mean Price | 26.69231 |
| Target Median Price | 25.0 |
| Total Cash | 304,724,992 |
| Total Cash Per Share | 6.57 |
| Total Debt | 1,987,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -20.06 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 21.993725 |
| Two Hundred Day Average Change | -9.393724 |
| Two Hundred Day Average Change Percent | -0.4271093 |
| Type Disp | Equity |
| Volume | 375,074 |
| Website | https://www.maplightrx.com |
| Zip | 94,063 |